APA (7th ed.) Citation

S, B., C, C., D, A., S, S., F, d. A. T., V, S., . . . R, D. L. (2026). Paediatric medicines development for Duchenne muscular dystrophy: An EU regulatory perspective. Journal of neuromuscular diseases, 13(3), 405. https://doi.org/10.1177/22143602251397736

Chicago Style (17th ed.) Citation

S, Benchetrit, Chu C, Athanasiou D, Scherer S, de Andres Trelles F, Stoyanova-Beninska V, Martinez-Lapiscina EH, and De Lisa R. "Paediatric Medicines Development for Duchenne Muscular Dystrophy: An EU Regulatory Perspective." Journal of Neuromuscular Diseases 13, no. 3 (2026): 405. https://doi.org/10.1177/22143602251397736.

MLA (9th ed.) Citation

S, Benchetrit, et al. "Paediatric Medicines Development for Duchenne Muscular Dystrophy: An EU Regulatory Perspective." Journal of Neuromuscular Diseases, vol. 13, no. 3, 2026, p. 405, https://doi.org/10.1177/22143602251397736.